Arbutus Biopharma Corp

Listed Company

ABUSCIK 0001447028NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsA1CAFY ends Dec 31

Period

FY 2025

Revenue

$14.08M

Net Income

$-33.50M

Total Assets

$94.62M

Equity

$76.58M

Shares Out

195.48M

Op. Cash Flow

$-39.64M

Business

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease, principally developing therapies for chronic hepatitis B and advancing its lipid nanoparticle (LNP) delivery technology through ownership and a license to Genevant. It develops imdusiran (AB-729), a GalNAc-conjugated subcutaneous RNAi therapeutic, and AB-101, an oral PD-L1 inhibitor, while seeking to maximize and license its LNP delivery platform and defend related intellectual property. Key activities include clinical development of cHBV product candidates, collaborations, licensing and royalty arrangements, and IP litigation. The company conducts global clinical trials, seeks regional partnerships (including Greater China and Taiwan), and pursues international patent enforcement and licensing channels.

Summary from filing dated 2025-03-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	14	6	18	39	11
Research and development	25	54	74	84	66
General and administrative	16	22	22	18	17
Change in fair value of contingent consideration	−2	3	69,000	2	2
Restructuring costs	13	4	0	—	0
Total operating expenses	52	82	96	104	85
Loss from operations	−38	−76	−78	−65	−74
Interest income	4	7	6	2	127,000
Gain on sale of property and equipment	674,000	0	—	—	—
Interest expense	−97,000	−137,000	−459,000	—	—
Foreign exchange gain / (loss)	14,000	−49,000	25,000	−22,000	5,000
Total other income	5	6	5	444,000	−3
Net loss	−34	−70	−73	−69	−76
Basic (in USD per share)	−0.17	−0.38	−0.44	−0.46	−0.83
Diluted (in USD per share)	−0.17	−0.38	−0.44	−0.46	−0.83
Basic (in shares)	192	186	166	151	106
Diluted (in shares)	192	186	166	151	106
Unrealized gain on available-for-sale securities	37,000	286,000	2	−2	—
Comprehensive loss	−33	−70	−71	−72	−76

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	18	36	26	31	109
Investments in marketable securities, current	73	86	100	116	46
Accounts receivable	1	2	2	1	899,000
Prepaid expenses and other current assets	2	2	4	3	4
Total current assets	94	127	132	151	161
Property and equipment, net of accumulated depreciation and impairment	32,000	3	5	5	6
Investments in marketable securities, non-current	0	0	6	37	36
Right of use asset	0	1	1	2	2
Other non-current assets	130,000	34,000	0	103,000	61,000
Total assets	95	132	144	195	204
Accounts payable and accrued liabilities	5	8	10	16	11
Deferred license revenue, current	0	8	12	16	0
Lease liability, current	547,000	483,000	425,000	372,000	383,000
Total current liabilities	6	16	22	33	11
Liability related to sale of future royalties	3	5	7	10	16
Deferred license revenue, non-current	0	3	0	6	0
Contingent consideration	8	10	8	8	5
Lease liability, non-current	199,000	806,000	1	2	2
Total liabilities	18	34	38	59	35
Issued and outstanding: 192,531,225 and 189,963,492 as of December 31, 2025 and 2024, respectively.	1,421	1,410	1,350	1,319	1,287
Additional paid-in capital	83	82	81	72	65
Deficit	−1,380	−1,347	−1,277	−1,204	−1,134
Accumulated other comprehensive loss	−48	−48	−48	−50	−48
Total stockholders' equity	77	97	106	137	169
Total liabilities and stockholders' equity	95	132	144	195	204

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	400,000	1	1	1	2
Stock-based compensation expense	7	9	9	7	6
Non-cash royalty revenue	−1	−2	−4	−8	−6
Non-cash interest expense	95,000	127,000	455,000	2	3
Restructuring, Settlement and Impairment Provisions	3	167,000	0	—	—
Net accretion of investments in marketable securities	−2	−3	−2	−54,000	999,000
Accounts receivable	1	−633,000	−424,000	−453,000	413,000
Prepaid expenses and other assets	2	2	−943,000	2	−1
Accounts payable and accrued liabilities	−2	−3	−6	5	2
Change in deferred license revenue	−10	−1	−11	22	0
Other liabilities	−557,000	−430,000	−444,000	−405,000	−374,000
Net cash used in operating activities	−40	−65	−86	−35	−68
Purchase of investments in marketable securities	−140	−142	−81	−130	−82
Disposition of investments in marketable securities	155	165	132	56	70
Proceeds from sale of property and equipment	364,000	0	20,000	0	—
Acquisition of property and equipment	0	−182,000	−1	−512,000	−809,000
Net cash provided by investing activities	16	23	51	−75	−13
Issuance of common shares pursuant to the Open Market Sale Agreement	0	44	30	20	135
Issuance of common shares pursuant to exercise of stock options	6	7	260,000	122,000	2
Issuance of common shares pursuant to ESPP	181,000	396,000	535,000	395,000	461,000
Net cash provided by financing activities	6	52	31	32	137
Effect of foreign exchange rate changes on cash and cash equivalents	14,000	−49,000	25,000	−22,000	5,000
(Decrease) / increase in cash and cash equivalents	−18	10	−4	−79	57

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro